Dystrophin Market
Dystrophin Market - Global Industry Assessment & Forecast
#
Pages:
168
Base Year:
2022
Jan - 2022
Format:
Report Code:
VMR-1251
Segments Covered
By
Product Exondys51, Translarna, Emflaza, Others
-
By
Approach Exon Skipping, Anti-Inflammatory Therapy, Stop Codon Read-Through, Others Approaches
-
By
Region North America, Latin America, Europe, Asia Pacific, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 1.46 Billion |
 Revenue 2030:
|
USD 29.53 Billion |
 Revenue CAGR
(2023 - 2030): |
45.60% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Dystrophin Market Segment Analysis
- Dystrophin Product Outlook (Revenue, USD Million, 2018 - 2030)
- Exondys51
- Translarna
- Emflaza
- Others
- Dystrophin Approach Outlook (Revenue, USD Million, 2018 - 2030)
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
-
North America Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- U.S.
- U.S. Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- U.S. Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- U.S. Dystrophin Market, by Product
- Canada
- Canada Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Canada Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Canada Dystrophin Market, by Product
-
Mexico
- Mexico Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Mexico Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Mexico Dystrophin Market, by Product
-
North America Dystrophin Market, by Product
- Europe
-
Europe Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
-
Europe Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- U. K.
- U.K. Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- U.K. Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- U.K. Dystrophin Market, by Product
- France
- France Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- France Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- France Dystrophin Market, by Product
-
Germany
- Germany Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Germany Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Germany Dystrophin Market, by Product
-
Italy
- Italy Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Italy Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Italy Dystrophin Market, by Product
-
Spain
- Spain Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Spain Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Spain Dystrophin Market, by Product
-
Rest of Europe
- Rest of Europe Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Rest of Europe Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Rest of Europe Dystrophin Market, by Product
-
Europe Dystrophin Market, by Product
- Asia Pacific
-
Asia Pacific Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
-
Asia Pacific Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- China
- China Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- China Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- China Dystrophin Market, by Product
- Japan
- Japan Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Japan Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Japan Dystrophin Market, by Product
-
Germany
- Germany Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Germany Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Germany Dystrophin Market, by Product
-
India
- India Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- India Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- India Dystrophin Market, by Product
-
South Korea
- South Korea Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- South Korea Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- South Korea Dystrophin Market, by Product
-
South East Asia
- South East Asia Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- South East Asia Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- South East Asia Dystrophin Market, by Product
-
Rest of Asia Pacific
- Rest of Asia Pacific Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Rest of Asia Pacific Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Rest of Asia Pacific Dystrophin Market, by Product
-
Asia Pacific Dystrophin Market, by Product
- Latin America
-
Latin America Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
-
Latin America Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Brazil
- Brazil Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Brazil Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Brazil Dystrophin Market, by Product
- Argentina
- Argentina Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Argentina Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Argentina Dystrophin Market, by Product
-
Rest of Latin America
- Rest of Latin America Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Rest of Latin America Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Rest of Latin America Dystrophin Market, by Product
-
Latin America Dystrophin Market, by Product
- Middle East & Africa
-
Middle East & Africa Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
-
Middle East & Africa Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- GCC Countries
- GCC Countries Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- GCC Countries Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- GCC Countries Dystrophin Market, by Product
- South Africa
- South Africa Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- South Africa Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- South Africa Dystrophin Market, by Product
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Dystrophin Market, by Product
- Exondys51
- Translarna
- Emflaza
- Others
- Rest of Middle East & Africa Dystrophin Market, by Approach
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
- Rest of Middle East & Africa Dystrophin Market, by Product
-
Middle East & Africa Dystrophin Market, by Product
- North America
Vantage Market
Research | 30-Jan-2022
FAQ
Frequently Asked Question
What is the global demand for Dystrophin in terms of revenue?
-
The global Dystrophin valued at USD 1.46 Billion in 2022 and is expected to reach USD 29.53 Billion in 2030 growing at a CAGR of 45.60%.
Which are the prominent players in the market?
-
The prominent players in the market are PTC Therapeutics, Sarepta Therapeutics, BioMarin Pharmaceutical Inc, Wave Life Sciences, Bristol-Myers Squibb and Catabasis, Pharmaceuticals among others..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 45.60% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Dystrophin include
- Emergence of Mutation-Specific Therapies, Rising Incidence of the Condition, and Improved Diagnostics
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Dystrophin in 2022.
